Search hospitals > Delaware > Newark
Christiana Care Health System-Christiana Hospital
Claim this profileNewark, Delaware 19711
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Lymphoma
Conducts research for Cancer
Conducts research for Breast cancer
466 reported clinical trials
14 medical researchers
Summary
Christiana Care Health System-Christiana Hospital is a medical facility located in Newark, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Lymphoma, Cancer, Breast cancer and other specialties. Christiana Care Health System-Christiana Hospital is involved with conducting 466 clinical trials across 667 conditions. There are 14 research doctors associated with this hospital, such as Gregory A. Masters, Michael Guarino, MD, Mark E. Borowsky, and Anthony Sciscione, DO.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Gregory A. MastersHelen F Graham Cancer Center6 years of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
133 reported clinical trials
213 drugs studied
Michael Guarino, MDChristiana Hospital8 years of reported clinical research
Studies Pancreatic Cancer
Studies Brain Tumor
4 reported clinical trials
7 drugs studied
Mark E. BorowskyJersey Shore Medical Center6 years of reported clinical research
Studies Fallopian Tube Cancer
Studies Ovarian Cancer
3 reported clinical trials
11 drugs studied
Anthony Sciscione, DOChristiana Hospital2 years of reported clinical research
Studies Premature Birth
Studies Induction of Labor
2 reported clinical trials
2 drugs studied
Clinical Trials running at Christiana Care Health System-Christiana Hospital
Lung Cancer
Prostate Cancer
Cancer
Breast Cancer
Colorectal Cancer
Pancreatic Cancer
Breast cancer
Ovarian Cancer
Brain Tumor
Small Cell Lung Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Christiana Care Health System-Christiana Hospital?
Christiana Care Health System-Christiana Hospital is a medical facility located in Newark, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Lymphoma, Cancer, Breast cancer and other specialties. Christiana Care Health System-Christiana Hospital is involved with conducting 466 clinical trials across 667 conditions. There are 14 research doctors associated with this hospital, such as Gregory A. Masters, Michael Guarino, MD, Mark E. Borowsky, and Anthony Sciscione, DO.
Where is Christiana Care Health System-Christiana Hospital located?
**Christiana Care Health System-Christiana Hospital**
Location: 4755 Ogletown-Stanton Road, Newark, DE 19718.
Christiana Hospital in Newark, Delaware, serves as the primary location for Christiana Care Health System, complemented by additional facilities such as the HealthCare Center at Christiana nearby.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Christiana Care Health System-Christiana Hospital, contact the billing department at billing@uhcc.com or call (410) 392-7033, Monday to Friday, 8 a.m. to 4:30 p.m. Financial counselors are available to guide you through the application process, which can be initiated in person, by phone, or by requesting materials in English or Spanish through their website, mail, or in person. For specific assistance, contact a representative at 302-623-7440, available Monday through Friday, 9 a.m. to 4 p.m.
What insurance does Christiana Care Health System-Christiana Hospital accept?
Christiana Care Health System-Christiana Hospital accepts a wide range of insurance plans, including but not limited to Aetna HMO/POS, Amerihealth HMO/Keystone, BCBS – DE/MD/Out of Area, Cigna HMO/PPO, and United Healthcare. Please note that as of January 1, 2024, ChristianaCare services will be out-of-network for Humana Medicare Advantage plans, with the exception of emergency services. Services will continue to be in-network for Humana Medicare Supplemental Plan members.
What awards or recognition has Christiana Care Health System-Christiana Hospital received?
Christiana Care Health System-Christiana Hospital in Newark, Delaware, is celebrated for its exceptional healthcare services, earning accolades such as the 2nd best health system for diversity and inclusion and the 29th best health system to work for in the United States by Forbes. It is also listed among America's 50 Best Hospitals by Healthgrades and consistently ranks high in national quality ratings by U.S. News & World Report and Newsweek. The hospital holds accreditations from prestigious organizations like The Joint Commission, The American Association of Blood Banks, and The American College of Radiology.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.